Opinion|Videos|December 31, 2024
BCG-Unresponsive NMIBC: Insights for Newer Treatment Modalities
Author(s)Katie S. Murray, DO, MS
Key Takeaways
- BCG-unresponsive NMIBC is defined by persistent or recurrent high-grade tumors or carcinoma in situ after adequate BCG therapy.
- This condition requires alternative therapeutic strategies or radical cystectomy due to the failure of BCG treatment.
Katie S. Murray, DO, offers advice to urologists considering the adoption of newer treatment modalities for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), encouraging them to integrate these therapies into practice in light of the positive clinical trial data while emphasizing the potential for improved patient outcomes and the importance of staying informed about evolving treatment options.
Advertisement
Episodes in this series
- What advice do you have for urologists considering the adoption of newer treatment modalities for BCG-unresponsive NMIBC, especially in light of the positive clinical trial data?
Advertisement
Related to this article
The approval is supported by data from the phase 3 VOLGA trial.
Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.
The recommendation is backed by data from the phase 3 LITESPARK-011 trial.
Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
3
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
4
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
5